Equity
Additional Paid-In Capital
ResMed Additional Paid-In Capital increased by 1.5% to $2.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.2%, from $1.99B to $2.13B. Over 4 years (FY 2021 to FY 2025), Additional Paid-In Capital shows an upward trend with a 5.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
An increase typically signals equity financing or the issuance of shares for employee compensation.
Detailed definition
This represents the amount of capital received from shareholders in excess of the par value of the common stock. It is g...
Peer comparison
High levels are common in growth-oriented tech companies that utilize stock-based compensation to attract talent.
Metric ID:
additional_paid_in_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.62B | $1.64B | $1.63B | $1.65B | $1.68B | $1.70B | $1.71B | $1.73B | $1.77B | $1.79B | $1.82B | $1.85B | $1.90B | $1.92B | $1.96B | $1.99B | $2.03B | $2.06B | $2.10B | $2.13B |
| QoQ Change | — | +1.3% | -0.9% | +1.0% | +2.2% | +1.2% | +0.5% | +1.1% | +2.5% | +1.1% | +1.8% | +1.4% | +2.6% | +1.5% | +1.7% | +1.7% | +2.2% | +1.4% | +2.0% | +1.5% |
| YoY Change | — | — | — | — | +3.7% | +3.5% | +5.0% | +5.1% | +5.3% | +5.3% | +6.6% | +6.9% | +7.0% | +7.4% | +7.4% | +7.7% | +7.2% | +7.2% | +7.4% | +7.2% |
Range$1.62B – $2.13B
CAGR+5.9%
Avg YoY Growth+6.2%
Median YoY Growth+7.0%
Current Streak17 quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is ResMed's additional paid-in capital?
- ResMed (RMD) reported additional paid-in capital of $2.13B in Q1 2026.
- How has ResMed's additional paid-in capital changed year-over-year?
- ResMed's additional paid-in capital increased by 7.2% year-over-year, from $1.99B to $2.13B.
- What is the long-term trend for ResMed's additional paid-in capital?
- Over 4 years (2021 to 2025), ResMed's additional paid-in capital has grown at a 5.8% compound annual growth rate (CAGR), from $1.62B to $2.03B.
- What does additional paid-in capital mean?
- Capital received from investors above the par value of the shares.